Yup. Good price action this morning.
Post# of 156888
(Total Views: 425)
Posted On: 09/15/2021 9:45:24 AM
Re: HHIGambler #103906
Yup. Good price action this morning.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).
- Waiting…
whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……
“This isn’t conspiracy, this is criminal suppression.” - Ohm
https://www.justice.gov/usao-sdny/pr/us-attor...r-programs
https://investorshangout.com/images/MYImages/..._3015.jpeg
???? What Leronlimab Does
• Target: CCR5 receptor (the same receptor people with the CCR5Δ32 mutation lack — like the “Berlin” and “London” patients who were cured after stem cell transplants).
• Effect: By binding CCR5, leronlimab blocks HIV entry into CD4 cells.
• Trial Data:
• In combination therapy trials, ~81% of patients achieved viral loads <50 copies/mL (suppression, not cure).
• As monotherapy, some patients maintained suppression for long stretches (months), but not universally.
⸻
???? Why It Might Be Seen as a “Cure”
• In theory, if you completely block CCR5 on all relevant cells, HIV can’t infect new cells.
• If existing infected reservoirs naturally decay without replenishment, the virus could eventually vanish.
• That’s exactly what happened in the Berlin/London patients — except through stem cell transplants with CCR5Δ32 donors, not a drug.
⸻
???? Why It Hasn’t Been Called a Cure (Yet)
1. HIV Reservoirs Persist
Leronlimab blocks new infection, but it doesn’t flush latent virus from cells. Once treatment stops, those reservoirs can reignite infection.
2. CCR5-Independent Pathways
Some HIV strains use CXCR4 or dual-tropism (CCR5 + CXCR4). Leronlimab won’t stop those.
3. Clinical Conservatism
Researchers avoid using the word “cure” unless patients remain off all therapy with no viral rebound for years. Leronlimab hasn’t shown that in trials.
⸻
???? So Could It Alone Cure HIV?
• In select cases (if someone’s virus is purely CCR5-tropic and their reservoirs naturally decay): maybe.
• But in the general population, it’s unlikely as a monotherapy cure. More realistic is using it as part of a cure combo approach…
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).
- Waiting… whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……
“This isn’t conspiracy, this is criminal suppression.” - Ohm
https://www.justice.gov/usao-sdny/pr/us-attor...r-programs
https://investorshangout.com/images/MYImages/..._3015.jpeg
???? What Leronlimab Does
• Target: CCR5 receptor (the same receptor people with the CCR5Δ32 mutation lack — like the “Berlin” and “London” patients who were cured after stem cell transplants).
• Effect: By binding CCR5, leronlimab blocks HIV entry into CD4 cells.
• Trial Data:
• In combination therapy trials, ~81% of patients achieved viral loads <50 copies/mL (suppression, not cure).
• As monotherapy, some patients maintained suppression for long stretches (months), but not universally.
⸻
???? Why It Might Be Seen as a “Cure”
• In theory, if you completely block CCR5 on all relevant cells, HIV can’t infect new cells.
• If existing infected reservoirs naturally decay without replenishment, the virus could eventually vanish.
• That’s exactly what happened in the Berlin/London patients — except through stem cell transplants with CCR5Δ32 donors, not a drug.
⸻
???? Why It Hasn’t Been Called a Cure (Yet)
1. HIV Reservoirs Persist
Leronlimab blocks new infection, but it doesn’t flush latent virus from cells. Once treatment stops, those reservoirs can reignite infection.
2. CCR5-Independent Pathways
Some HIV strains use CXCR4 or dual-tropism (CCR5 + CXCR4). Leronlimab won’t stop those.
3. Clinical Conservatism
Researchers avoid using the word “cure” unless patients remain off all therapy with no viral rebound for years. Leronlimab hasn’t shown that in trials.
⸻
???? So Could It Alone Cure HIV?
• In select cases (if someone’s virus is purely CCR5-tropic and their reservoirs naturally decay): maybe.
• But in the general population, it’s unlikely as a monotherapy cure. More realistic is using it as part of a cure combo approach…